ple-blind, placebo-controlled, parallel-group, pivotal clinical study designedafter consultation with the U.S. Food andDrug Administration to evaluate glycemiccontrol, as assessed by HbA 1c, and safety. The study commenced with a 4-week, single-blind, lead-in period with subcuta-neous injection of placebo twice daily.Thereafter, subjects were randomized to Figure 1— Study ﬂow chart and subject baseline demographics. Values are means /H11006SD or n (%).Buse and Associates DIABETES CARE,VOLUME 27, NUMBER 11, N OVEMBER 2004 2629